within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD14_SusoctocogAlfa;

model SusoctocogAlfa
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5.4444444444444444e-08,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 4.6e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>SusoctocogAlfa</td></tr><tr><td>ATC code:</td><td>B02BD14</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.046</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.8</td><td>mL/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Susoctocog alfa is a recombinant, factor VIII (FVIII) replacement therapy derived from human cell-line, used for the treatment and prevention of bleeding episodes and perioperative management in patients with congenital hemophilia A who have developed inhibitors to FVIII. It is used as a bypassing agent and is currently approved for clinical use in this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for susoctocog alfa are reported in adult hemophilia A patients with FVIII inhibitors.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B02BD14 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end SusoctocogAlfa;
